Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Retained Earnings (2018 - 2025)

Addex Therapeutics' Retained Earnings history spans 8 years, with the latest figure at -$450.5 million for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 1370.58% to -$450.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$450.5 million, a 1370.58% decrease, with the full-year FY2025 number at -$434.3 million, down 1324.84% from a year prior.
  • Retained Earnings came in at -$450.5 million for Q4 2025, down from -$447.9 million in the prior quarter.
  • The five-year high for Retained Earnings was $35.5 million in Q4 2024, with the low at -$450.5 million in Q4 2025.
  • Historically, Retained Earnings has averaged -$347.4 million across 5 years, with a median of -$384.3 million in 2024.
  • Biggest five-year swings in Retained Earnings: plummeted 1619.06% in 2023 and later surged 108.73% in 2024.
  • Year by year, Retained Earnings stood at -$356.9 million in 2021, then skyrocketed by 107.5% to $26.7 million in 2022, then crashed by 1619.06% to -$406.3 million in 2023, then soared by 108.73% to $35.5 million in 2024, then crashed by 1370.58% to -$450.5 million in 2025.
  • Business Quant data shows Retained Earnings for ADXN at -$450.5 million in Q4 2025, -$447.9 million in Q3 2025, and -$430.8 million in Q2 2025.